Evidence map›Paper›PMID 41556090›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Alkaline Phosphatase-Activated NIR-II AIEgens Nanosystem for Surgical and Postoperative Closed-Loop Therapy of Advanced Osteosarcoma.

Kaiyuan Liu, Ruotong Li, Li Zhang, Hengli Lu, Binhui Yang, Qian Hu, Yining Tao, Haoran Mu, Jing Han, Pengfei Zan and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Kaiyuan LiuSchool of Physical Science and Technology & State Key Laboratory of Advanced Medical Materials and Devices, ShanghaiTech University, Shanghai, P. R. China.
Ruotong LiSchool of Physical Science and Technology & State Key Laboratory of Advanced Medical Materials and Devices, ShanghaiTech University, Shanghai, P. R. China.
Li ZhangDepartment of Dermatology, Shanghai Key Laboratory of Molecular Medical Mycology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, P. R. China.
Hengli LuDepartment of Bone Tumor Surgery, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, P. R. China.
Binhui YangDepartment of Bone Tumor Surgery, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, P. R. China.
Qian HuSchool of Physical Science and Technology & State Key Laboratory of Advanced Medical Materials and Devices, ShanghaiTech University, Shanghai, P. R. China.
Yining TaoDepartment of Bone Tumor Surgery, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, P. R. China.
Haoran MuDepartment of Bone Tumor Surgery, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, P. R. China.
Jing HanDepartment of Bone Tumor Surgery, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, P. R. China.
Pengfei ZanDepartment of Bone Tumor Surgery, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, P. R. China.
Jiakang ShenDepartment of Bone Tumor Surgery, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, P. R. China.
Dongqing ZuoDepartment of Bone Tumor Surgery, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, P. R. China.
Hongsheng WangDepartment of Bone Tumor Surgery, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, P. R. China.
Wei SunDepartment of Bone Tumor Surgery, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, P. R. China.
Xingjun ZhuSchool of Physical Science and Technology & State Key Laboratory of Advanced Medical Materials and Devices, ShanghaiTech University, Shanghai, P. R. China.ORCID https://orcid.org/0000-0002-7507-1781

Funding

National Natural Science Foundation of China 82001945National Natural Science Foundation of China 82373177Natural Science Foundation of Shanghai 24ZR1452300Shanghai Clinical Research and Trial CenterShanghai Jiao Tong University "SJTU Star" Medical Engineering Interdisciplinary Research Fund YG2023LC09Shanghai Sailing Program 23YF1434400ShanghaiTech University
6 · The paper itself

Abstract

In advanced osteosarcoma, tumor invasion often prevents complete resection, and immunotherapy is limited by the tumor's immunosuppressive nature, making residual lesions a key source of recurrence. To address this, we developed an ALP-responsive theranostic nanoplatform (SGPF) integrating an AIEgens (STEA) and HSP90 inhibitor (Ganetespib) for imaging-guided resection and multimodal therapy. Selenium-doped STEA enables NIR-IIb imaging and enhanced phototherapy via narrowed HOMO-LUMO gaps and nonradiative decay optimization. At tumor sites, ALP-triggered nanomicelle cleavage releases STEA and Ganetespib while vaporizing perfluorohexane to relieve hypoxia. NIR irradiation induces pyroptosis via caspase-3/GSDME activation and immunogenic cell death, while Ganetespib suppresses glycolysis (HK2/PKM2 downregulation) to reverse lactate-driven immunosuppression. This dual-action strategy synergistically enhances T-cell infiltration and ablates residual/metastatic lesions, offering a transformative approach for unresectable Osteosarcoma.

Indexed as

Alkaline PhosphataseBone NeoplasmsOsteosarcomaAnimalsCell Line, TumorHumansMiceNanoparticlesAlkaline Phosphataseaggregation‐induced emission (AIE)alkaline phosphatase (ALP)immunotherapyosteosarcomaphotothermal/photodynamic therapy (PTT/PDT)

Identifiers

PMID41556090
PMCPMC13042677

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.